Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Phase 1b: Primary Objective: - To determine the recommended Phase 2 dose (RP2D) of ibrutinib in combination with everolimus in RCC, paclitaxel in urothelial carcinoma, docetaxel in gastric adenocarcinoma and cetuximab in CRC. Phase 2: Primary Objectives: - To assess progression-free survival (PFS) of ibrutinib combination therapy in RCC and urothelial carcinoma, and to assess the ORR of ibrutinib combination therapy in gastric adenocarcinoma and CRC
Critère d'inclusion
- Metastatic renal cell carcinoma (RCC), advanced urothelial carcinoma, advanced gastric (including gastro-esophageal [GEJ]) adenocarcinoma, and metastatic colorectal adenocarcinoma (CRC)